ClinicalTrials.gg
Not yet recruitingNCT07676734HIP-3BUpdated Jun 30, 2026

Comparison of Three Analgesic Strategies for Hip Fracture Surgery

An interventional study of Quadro-Iliac Plane Block and Suprainguinal Fascia Iliaca Block in Hip Fracture, sponsored by Başakşehir Çam & Sakura City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Başakşehir Çam & Sakura City Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Hip fracture surgery is associated with significant postoperative pain and increased opioid requirements. Regional anesthesia techniques may improve analgesia and reduce opioid consumption. This prospective, randomized, double-blind, controlled trial aims to compare the postoperative analgesic efficacy of Quadro-Iliac Plane Block (QIPB), Suprainguinal Fascia Iliaca Block (SIFIB), and standard analgesia in patients undergoing hip fracture surgery under spinal anesthesia. The primary outcome is cumulative tramadol consumption during the first 24 postoperative hours. Secondary outcome measures include postoperative pain intensity, rescue analgesic requirement, incidence of postoperative nausea and vomiting, Quality of Recovery-15 (QoR-15) score, and patient satisfaction score.

Read the detailed description

Hip fracture surgery is frequently associated with severe postoperative pain, delayed mobilization, and increased opioid consumption. Regional anesthesia techniques have been increasingly used to improve postoperative analgesia and reduce opioid-related adverse effects.

This prospective, randomized, double-blind, controlled, multicenter study aims to compare the postoperative analgesic efficacy of Quadro-Iliac Plane Block (QIPB), Suprainguinal Fascia Iliaca Block (SIFIB), and standard analgesia in patients undergoing hip fracture surgery under spinal anesthesia. Patients will be randomly allocated in a 1:1:1 ratio to one of the three study groups.

All surgical procedures will be performed under spinal anesthesia. Patients assigned to the QIPB group will receive ultrasound-guided quadro-iliac plane block, whereas patients assigned to the SIFIB group will receive ultrasound-guided suprainguinal fascia iliaca block. Patients in the control group will receive standard multimodal analgesia without a regional block.

The primary outcome measure is cumulative tramadol consumption during the first 24 postoperative hours. Secondary outcomes include postoperative pain scores, rescue analgesic requirements, time to first rescue analgesia, postoperative nausea and vomiting, quality of recovery assessed with the Quality of Recovery-15 (QoR-15) questionnaire, patient satisfaction, intraoperative opioid consumption, and block-related complications.

The study is planned to enroll 90 patients across three centers.

02

Conditions studied

  • Hip Fracture

Browse trials for

Keywords

  • Quadro-Iliac Plane Block
  • Suprainguinal Fascia Iliaca Block
  • Regional Anesthesia
  • Postoperative Analgesia
  • Spinal Anesthesia
  • Tramadol Consumption
  • QoR-15
  • Hip Fracture Surgery
03

In context

Hip Fractures

842 studies on the registry are indexed under Hip Fractures; 165 are open to participants now.

This study's planned enrollment of 90 is close to the median of 86 across 533 interventional studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

Başakşehir Çam & Sakura City Hospital is the lead sponsor of 109 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years or older
  • Patients scheduled for hip fracture surgery under spinal anesthesia
  • (ASA) physical status I-III
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • to spinal anesthesia
  • Contraindications to regional anesthesia
  • Allergy to local anesthetics or study medications
  • Infection at the injection site
  • Coagulopathy or anticoagulant therapy precluding regional block
  • Cognitive impairment preventing pain assessment
  • Chronic opioid use
  • Revision surgery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Quadro-Iliac Plane Block Group

    Patients assigned to this group will receive ultrasound-guided quadro-iliac plane block in addition to standard multimodal analgesia following hip fracture surgery performed under spinal anesthesia.

    Procedure: Quadro-Iliac Plane Block

  • Experimental
    Suprainguinal Fascia Iliaca Block Group

    Patients assigned to this group will receive ultrasound-guided suprainguinal fascia iliaca block in addition to standard multimodal analgesia following hip fracture surgery performed under spinal anesthesia.

    Procedure: Suprainguinal Fascia Iliaca Block

  • Active comparator
    Standard Analgesia Group

    Patients assigned to this group will receive standard multimodal analgesia without a regional block following hip fracture surgery performed under spinal anesthesia.

    Other: Standard Multimodal Analgesia

Interventions

  • ProcedureQuadro-Iliac Plane Block

    Ultrasound-guided quadro-iliac plane block will be performed following spinal anesthesia in patients undergoing hip fracture surgery. The block will be administered in addition to standard multimodal analgesia.

  • ProcedureSuprainguinal Fascia Iliaca Block

    Ultrasound-guided suprainguinal fascia iliaca block will be performed following spinal anesthesia in patients undergoing hip fracture surgery. The block will be administered in addition to standard multimodal analgesia.

  • OtherStandard Multimodal Analgesia

    Patients assigned to the control group will receive standard multimodal analgesia without a regional block following hip fracture surgery performed under spinal anesthesia.

06

What researchers measure

Primary outcomes

  1. Cumulative Tramadol Consumption During the First 24 Postoperative Hours

    The total amount of tramadol administered during the first 24 postoperative hours will be recorded and compared among the study groups.

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Postoperative Pain Intensity at Rest

    Postoperative pain intensity at rest will be assessed using the 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: At 0, 2, 6, 12, and 24 hours after surgery

  2. Time to First Rescue Analgesia

    Time from completion of surgery to the first administration of rescue analgesia, measured in hours.

    Time frame: Within the first 24 hours after surgery

  3. Rescue Analgesic Requirement

    The proportion of patients requiring rescue analgesia during the first 24 hours after surgery.

    Time frame: Within the first 24 hours after surgery

  4. Incidence of Postoperative Nausea and Vomiting

    The incidence of postoperative nausea and/or vomiting during the first 24 hours after surgery will be recorded.

    Time frame: Within the first 24 hours after surgery

  5. Quality of Recovery-15 (QoR-15) Score

    Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery.

    Time frame: 24 hours after surgery

  6. Patient Satisfaction Score

    Patient satisfaction with postoperative pain management will be assessed using a numerical rating scale scored between 0 and 10 at postoperative 24 hours (0 = not satisfied at all, 10 = completely satisfied). Higher scores indicate greater patient satisfaction.

    Time frame: 24 hours after surgery

  7. Block-related Complications

    The incidence of block-related complications, including local anesthetic systemic toxicity, vascular puncture, hematoma, infection, and persistent sensory or motor deficits, will be recorded.

    Time frame: During the first 24 hours after surgery.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data will not be made publicly available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2027, 6 months later.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 6 months is below that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 30, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07676734
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

muzaffer Gencer
Contact
dr.m.gencer07@gmail.com
+905059436459
kenan kart, md
Contact
kenankart@karabuk.edu.tr
5063849983
Kenan Kart
principal investigator · Karabuk University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion